Cardiac remodeling in systemic hypertension

Area of Science:

• Cardiology
• Hypertension Research
• Cardiac Pathophysiology

Background:

• Hypertension is linked to adverse cardiac structural and functional changes.
• These include left atrial enlargement, left ventricular hypertrophy (LVH), myocardial fibrosis, and impaired systolic/diastolic function.
• Both hemodynamic and nonhemodynamic factors contribute to these changes.

Purpose of the Study:

• To review the evidence on antihypertensive therapy's role in preventing and reversing cardiac changes associated with hypertension.
• To highlight the importance of preventing LVH in hypertensive patients.
• To discuss future therapeutic targets for hypertensive heart disease.

Main Methods:

• Review of experimental and clinical studies.
• Analysis of data from small and large clinical trials on antihypertensive therapies.
• Evaluation of the impact of therapy on LVH, myocardial fibrosis, cardiac function, and cardiovascular outcomes.

Main Results:

• Various antihypertensive therapies are effective in preventing and regressing LVH and myocardial fibrosis.
• Reversal of LVH is associated with improved cardiac function and reduced cardiovascular event risk.
• Prevention of LVH is a critical goal in managing hypertension.

Conclusions:

• Antihypertensive therapy plays a key role in managing hypertensive heart disease by optimizing blood pressure and regressing LVH.
• Future therapeutic strategies should aim for myocardial fibrosis regression, LA size normalization, and improved LV diastolic function.
• Comprehensive management of hypertensive heart disease requires addressing both blood pressure control and cardiac remodeling.